Another target identified in the treatment of NAFLD are fatty acid synthesis (FASN) associated genes and sterol regulatory element-binding protein 1 (SREBP-1C), a transcription factors that controls de novo lipogenesis through the induction of lipogenic enzymes that stimulate steatosis [70]. Here, SREBF1 is linked to steatosis.